Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

8296	Companies
114905	Keywords
55332	Articles
62461	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 07/11/2024 at 07:01, 4 months 10 days ago

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
Biophytis obtains FDA approval to start phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by Prof. Marc-André Cornier to start mid-2024 in the USA

Biophytis FDA Approval Obesity Treatment BIO101 Phase 2 OBA Study
BRIEF

published on 07/01/2024 at 07:05, 4 months 20 days ago

Biophytis Presents Promising Phase 2-3 COVA Study Results on Severe Covid-19 at WCID in Paris

Biophytis COVID-19 Clinical Trials COVA Study Infectious Diseases
PRESS RELEASE

published on 07/01/2024 at 07:00, 4 months 20 days ago

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris
Biophytis presents positive results from Phase 2-3 COVA study for severe Covid-19 at WCID Paris. Bio101 shows significant efficacy and safety in reducing risk of respiratory failure and death

Biophytis COVID-19 Positive Results Phase 2-3 COVA Study Respiratory Failure
REGULATED PRESS RELEASE

published on 07/01/2024 at 07:00, 4 months 20 days ago

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris
Biophytis presented positive results of its Phase 2-3 COVA study for severe Covid-19 at WCID in Paris, showing reduction in respiratory failure and death rates

Biophytis COVID-19 Positive Results Phase 2-3 COVA Study
BRIEF

published on 06/25/2024 at 23:05, 4 months 25 days ago

Biophytis Approves All Resolutions at General Meeting

Shareholders Biophytis General Meeting Resolutions
REGULATED PRESS RELEASE

published on 06/25/2024 at 23:00, 4 months 25 days ago

RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024
Biophytis SA announces the approval of all resolutions at the combined general meeting held on June 24, 2024, with significant shareholder participation

Shareholders General Meeting Resolutions Approval Biophytis SA
BRIEF

published on 06/20/2024 at 07:05, 5 months 1 day ago

Biophytis Grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at Up to €108 Million

Biophytis Pharmaceuticals Latin America BIO101 Blanver
PRESS RELEASE

published on 06/20/2024 at 07:00, 5 months 1 day ago

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 million. Agreement includes upfront and milestones payments, double-digit royalties, and collaboration on manufacturing and clinical development

Biophytis Latin America Exclusive Rights Blanver Pharmaceutical Deal
REGULATED PRESS RELEASE

published on 06/20/2024 at 07:00, 5 months 1 day ago

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million. Collaboration for commercialization and clinical development announced

Biophytis Latin America BIO101 Exclusive Rights Blanver
BRIEF

published on 06/20/2024 at 01:15, 5 months 1 day ago

Biophytis extends its contract with Atlas to finance its clinical activities

Biophytis Biotechnology Convertible Bonds Funding Atlas

Accesswire

Published on 11/21/2024 at 13:30, 29 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 29 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 59 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 59 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 59 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 43 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 23 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 44 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 52 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 58 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 1 minute ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 39 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 14 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 14 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE